the fullness thing is the part people describe differently, food stops being interesting rather than repellent, still working it out
#cagrilintide 2026-05-24
- see_a_clinician — the fullness thing is the part people describe differently, food stops being interesting rather than repellent, still working it out 18:40
- see_a_clinician — anyone got two VendorInvestigate results on the same QST lot for this 18:58
- see_a_clinician — i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something €38 for a 5 vial and it lasts me longer than the GLP-1 does at my… 19:03
monotherapy here
i keep the two on separate days so if something goes wrong i have a chance of knowing which
anyone got two VendorInvestigate results on the same QST lot for this
anyone dosing this on a different day to their tirzepatide
held mine a while
i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something
€38 for a 5 vial and it lasts me longer than the GLP-1 does at my doses
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
held at 12 for 4 months on monotherapy before i touched it again, take that with a pinch of salt
stopped for 6 months and the fullness went within a fortnight of the last dose
the reason nausea reads differently is timing, mine arrived on the second day rather than the first, ill dig out the number
did anyone find monotherapy underwhelming
has REDEFINE reported or are people quoting earlier work
i was sceptical about monotherapy and after 17 months im still sceptical, just less so
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake, still working it out
follow up is there a reason people titrate this over more weeks than the others
slower than the others
is anyone running this on its own or is it all CagriSema in here
[edited]